About
Proprietary biparatopic nanobody platform
Areas of Focus
Categories
Biologics & BiopharmaceuticalBiotech
Team (19)
Aaron Royston
Aaron Royston, M.D., MBADirector
Attovia Therapeutics
team_member
Angie You
Angie You, Ph.D.Director
Attovia Therapeutics
team_member
Bora Han
Bora Han, Ph.D.
Attovia Therapeutics
team_member
Colin Walsh
Colin Walsh, Ph.D.Director
Attovia Therapeutics
team_member
David Bellovin
David Bellovin, Ph.D.
Attovia Therapeutics
team_member
David King
David King, Ph.D.
Attovia Therapeutics
team_member
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
176
By Phase
PHASE1: 2
By Status
NOT_YET_RECRUITING: 1RECRUITING: 1
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT07205081Lead Sponsor
Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis
PHASE1Not yet recruiting
72 participants
Started: Oct 31, 2025 · Completed: Oct 31, 2026
NCT06787586Lead Sponsor
Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus
PHASE1Recruiting
104 participants
Started: Jan 14, 2025 · Completed: May 31, 2026
Locations (1)
Headquarters
San Carlos, CA, United States
Map
Loading map...